LYON, France--(BUSINESS WIRE)--POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, today announced the addition of Janice Bourque, Managing Director of Hercules Technology Growth Capital, and Pierre Legault, President and CEO of Nephrogenex Inc, to its Board of Directors. Both appointments were approved by Poxel’s shareholders at the Annual Shareholder Meeting held in Paris last Friday, January 29, 2016.
